AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36388001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Approach (CBA)
Number of subjects: 367
Study 36388001 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 367
Study 36388199 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary team work using ICF model as a guide
Number of subjects: 0
Study 36388199 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary teamwork implementing neuroproprioceptive 'facilitation and inhibition' physiotherapy
Number of subjects: 0
Study 36388199 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary teamwork implementing technology-based physiotherapy
Number of subjects: 0
Study 36388199 — intervention group
Group type: COMPARATOR
Intervention: Standard multidisciplinary teamwork
Number of subjects: 0
Study 36388237 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-Carbidopa Intestinal Gel (LCIG)
Number of subjects: 87
Study 36388237 — intervention group
Group type: COMPARATOR
Intervention: Optimized Medical Treatment (OMT)
Number of subjects: 87
Study 36389188 — intervention group
Group type: EXPERIMENTAL
Intervention: OviTex® 1S
Number of subjects: 92
Study 36389246 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile feedback insole
Number of subjects: 4
Study 36389246 — intervention group
Group type: COMPARATOR
Intervention: No feedback insole
Number of subjects: 4
Study 36389355 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (5 daily drops for 4 weeks)
Number of subjects: 49
Study 36389355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 49
Study 36389766 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (IL-1 receptor antagonist)
Number of subjects: 0
Study 36394153 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06939999 at 0.5 mg, 4 mg, 6 mg, or 8 mg once daily (q.d.) or 0.5 mg, 1 mg, 2 mg, 4 mg, or 6 mg twice daily (b.i.d.)
Number of subjects: 28
Study 36394153 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06939999
Number of subjects: 28
Study 36394250 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Behavioral Therapy (MBCBT)
Number of subjects: 44
Study 36394250 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (Control)
Number of subjects: 44
Study 36394495 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led multi-component behavioural activation (N-MBA) programme
Number of subjects: 40
Study 36394495 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 36394530 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes continual reassessment method (PRO-CRMB)
Number of subjects: 0
Study 36394530 — intervention group
Group type: COMPARATOR
Intervention: 5 + 2 stepwise design
Number of subjects: 0
Study 36394692 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-based analysis using prismaLine, Loewenstein Medical Technology
Number of subjects: 50
Study 36394692 — intervention group
Group type: COMPARATOR
Intervention: Monitored polysomnography (PSG)
Number of subjects: 50
Study 36394867 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 800 mg every 2 weeks and Talazoparib 1 mg once daily
Number of subjects: 200
Study 36394892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence lifetime imaging ophthalmoscopy (short spectral channel)
Number of subjects: 19
Study 36394892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence lifetime imaging ophthalmoscopy (long spectral channel)
Number of subjects: 19
Study 36395084 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue Light-Emitting Diode Therapy
Number of subjects: 0
Study 36395401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept 4 mg/kg intravenously on day 1 and 15 of a 28-day cycle (reduced to 2 mg/kg due to hypertension-related events)
Number of subjects: 19
Study 36395492 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS Microinjector® with triamcinolone acetonide injectable suspension (Xipere®)
Number of subjects: 0
Study 36395492 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS Microinjector®
Number of subjects: 0
Study 36395818 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 215
Study 36395818 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 215
Study 36395989 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg/day for 8 weeks
Number of subjects: 0
Study 36396038 — intervention group
Group type: EXPERIMENTAL
Intervention: International Classification of Diseases codes
Number of subjects: 51059
Study 36396038 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth certificate diagnosis
Number of subjects: 51059
Study 36396301 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel care pathway
Number of subjects: 0
Study 36396301 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 0
Study 36396307 — intervention group
Group type: EXPERIMENTAL
Intervention: IMU-838 + oseltamivir
Number of subjects: 0
Study 36396307 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 0
Study 36396416 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed medical care (more than once)
Number of subjects: 0
Study 36396416 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed behavioral health care (more than once)
Number of subjects: 0
Study 36396416 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who delayed care multiple times
Number of subjects: 0
Study 36396416 — intervention group
Group type: COMPARATOR
Intervention: Participants who delayed care once or did not delay
Number of subjects: 0
Study 36396498 — intervention group
Group type: EXPERIMENTAL
Intervention: Oteseconazole (VIVOJA)
Number of subjects: 0
Study 36396665 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with pyrotinib, letrozole, and dalpiciclib (5 cycles of 4-week treatment)
Number of subjects: 79
Study 36396665 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with pyrotinib, letrozole, and dalpiciclib
Number of subjects: 79
Study 36396738 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 0
Study 36396738 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 36396947 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled feeding by uninfected Aedes aegypti mosquitos
Number of subjects: 30
Study 36397054 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MRI evaluation using the semi-quantitative MRI OA Knee Scoring (MOAKS) system
Number of subjects: 289
Study 36397054 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in MRI features over 24 months
Number of subjects: 289
Study 36398319 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroRNA-15b/-106a/-374a impairment via transduction of human CD14 + monocytes
Number of subjects: 677
Study 36398319 — intervention group
Group type: COMPARATOR
Intervention: No AMR samples
Number of subjects: 677
Study 36398439 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat (5 mg/week) plus exemestane (25 mg/day)
Number of subjects: 133
Study 36398439 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus exemestane (25 mg/day)
Number of subjects: 133
Study 36398795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (cohort 4)
Number of subjects: 108
Study 36398795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus lenalidomide (cohort 5)
Number of subjects: 108
Study 36398879 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed, home-based walking intervention (150 min/week) using an activity tracker (FitbitTM)
Number of subjects: 60
Study 36398879 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed, home-based walking intervention
Number of subjects: 60
Study 36398903 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower blood pressure targets (135/85 mmHg or less)
Number of subjects: 9595
Study 36398903 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure targets (140 mmHg to 160mmHg/90 mmHg to 100 mmHg or less)
Number of subjects: 9595
Study 36399037 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus tivozanib
Number of subjects: 0
Study 36399068 — intervention group
Group type: EXPERIMENTAL
Intervention: JDQ443, a structurally novel, pyrazole-based, covalent inhibitor of KRAS
Number of subjects: 0
Study 36399070 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0
Study 36399131 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy
Number of subjects: 19
Study 36399131 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma neurofilament light chain (NfL) concentration
Number of subjects: 19
Study 36399169 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Stress Management Toolkit (including animatronic social pets, weighted blankets, aromatherapy, etc.)
Number of subjects: 10
Study 36399169 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Stress Management Toolkit
Number of subjects: 10
Study 36399172 — intervention group
Group type: EXPERIMENTAL
Intervention: LGMDR9 participants
Number of subjects: 8
Study 36399178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) - regular cohort (3 initial monthly injections followed by injections every 2 months)
Number of subjects: 516
Study 36399178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) - irregular cohort with initial monthly injections
Number of subjects: 516
Study 36399178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) - irregular cohort without initial monthly injections
Number of subjects: 516
Study 36399214 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive intracranial pressure waveforms (NICPW)
Number of subjects: 72
Study 36399237 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS-TA 4.0 mg (0.1 ml of 40 mg/ml)
Number of subjects: 155
Study 36399237 — intervention group
Group type: COMPARATOR
Intervention: Control (sham)
Number of subjects: 155
Study 36399237 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS-TA 4.0 mg
Number of subjects: 155
Study 36399441 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified gating strategy
Number of subjects: 62
Study 36399441 — intervention group
Group type: COMPARATOR
Intervention: Original gating strategy
Number of subjects: 62
Study 36399457 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome assessment and cognitive function tests
Number of subjects: 360
Study 36399457 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic tissue biopsies and brain imaging
Number of subjects: 360
Study 36399518 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residual disease (MRD) detected in apheresis stem cell (ASC) samples
Number of subjects: 159
Study 36399518 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive plasma MRD result post-ASCT
Number of subjects: 159
Study 36399518 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive ASC MRD
Number of subjects: 159
Study 36399518 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ASCT surveillance MRD testing of plasma
Number of subjects: 159
Study 36399518 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study results
Number of subjects: 159
Study 36399695 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 0
Study 36399695 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36399701 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-22 (F-652) combined with systemic corticosteroids
Number of subjects: 27
Study 36399997 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin intervention group (n = 30)
Number of subjects: 60
Study 36399997 — intervention group
Group type: COMPARATOR
Intervention: Health education control group (n = 30)
Number of subjects: 60
Study 36400018 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome (WG) methylation
Number of subjects: 0
Study 36400018 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nucleotide variants with paired white blood cell background removal
Number of subjects: 0
Study 36400018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined scores from classifiers evaluated in this study
Number of subjects: 0
Study 36400018 — intervention group
Group type: EXPERIMENTAL
Intervention: cTAF (circulating tumor allele fraction)
Number of subjects: 0
Study 36400018 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical limit of detection (LOD) approaches
Number of subjects: 0
Study 36400018 — intervention group
Group type: EXPERIMENTAL
Intervention: WG methylation feature
Number of subjects: 0
Study 36400069 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib 160 mg twice daily or 320 mg once daily
Number of subjects: 67
Study 36400069 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 67
Study 36400106 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanidatamab 20 mg/kg every 2 weeks (Part 2)
Number of subjects: 132
Study 36400106 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanidatamab (Part 1)
Number of subjects: 132
Study 36400106 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanidatamab (Part 2)
Number of subjects: 132
Study 36400177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative tobacco smoke exposure (TSE)
Number of subjects: 476
Study 36400177 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational vitamin D
Number of subjects: 476
Study 36400184 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT HEART Pathway (derivation cohort)
Number of subjects: 1452
Study 36400184 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT HEART Pathway (validation cohort)
Number of subjects: 1452
Study 36400410 — intervention group
Group type: COMPARATOR
Intervention: HbA1c < 5.7% (Q1)
Number of subjects: 3994
Study 36400410 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.7% ≤ HbA1c < 6.1% (Q2)
Number of subjects: 3994
Study 36400410 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.1% ≤ HbA1c < 6.9% (Q3)
Number of subjects: 3994
Study 36400410 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c ≥ 6.9% (Q4)
Number of subjects: 3994
Study 36400531 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 36401081 — intervention group
Group type: EXPERIMENTAL
Intervention: OC-01 (varenicline solution) nasal spray 0.03 mg
Number of subjects: 449
Study 36401081 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (VC)
Number of subjects: 449
Study 36401179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix HPV vaccination
Number of subjects: 12118
Study 36401179 — intervention group
Group type: COMPARATOR
Intervention: No HPV vaccination
Number of subjects: 12118
Study 36401237 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic variability measured using continuous glucose monitoring system (CGMS) over a 10-day period
Number of subjects: 150
Study 36401237 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported questionnaires assessing eating behaviors, diabetes self-management skills, anxiety disorders, depression disorder, diabetes literacy and numeracy skills, cognitive flexibility, attention deficit, level of interoception, and impulsivity behaviors
Number of subjects: 150
Study 36401237 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative phase with individual in-depth face-to-face (virtual) interviews
Number of subjects: 150
Study 36401271 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel disposable, self-inserted vaginal device
Number of subjects: 52
Study 36401271 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 52
Study 36401320 — intervention group
Group type: EXPERIMENTAL
Intervention: Labour inspections
Number of subjects: 0
Study 36401320 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance-through-workshops led by inspectors
Number of subjects: 0
Study 36401320 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36401338 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal RAT
Number of subjects: 41
Study 36401338 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva RAT
Number of subjects: 41
Study 36401338 — intervention group
Group type: COMPARATOR
Intervention: CTN swab PCR
Number of subjects: 41
Study 36401636 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based attenuation corrected (DLAC) polar maps
Number of subjects: 722
Study 36401636 — intervention group
Group type: COMPARATOR
Intervention: Non-attenuation-corrected (NAC) polar maps
Number of subjects: 722
Study 36401636 — intervention group
Group type: COMPARATOR
Intervention: Consensus of expert readers
Number of subjects: 722
Study 36401732 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0810 100-800 mg once daily or 300-400 mg twice daily
Number of subjects: 152
Study 36401732 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0810 600 mg QD taken with food
Number of subjects: 152
Study 36401732 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0810
Number of subjects: 152
Study 36401761 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg (UPA15)
Number of subjects: 272
Study 36401761 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg (UPA30)
Number of subjects: 272
Study 36401761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 36401886 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose, B12-vitamin, and folic acid administered 1 day before surgery.
Number of subjects: 442
Study 36401886 — intervention group
Group type: COMPARATOR
Intervention: Control group (not screened for ID).
Number of subjects: 442
Study 36402009 — intervention group
Group type: EXPERIMENTAL
Intervention: Every additional cup of tea or coffee per day
Number of subjects: 26318
Study 36402009 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g/day increment of dietary protein intake
Number of subjects: 26318
Study 36402023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic-floor muscle training (PFMT)
Number of subjects: 106
Study 36402023 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial levels of depression
Number of subjects: 106
Study 36402023 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of PFMT programme
Number of subjects: 106
Study 36402082 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior incarceration
Number of subjects: 201
Study 36402146 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 30 mg orally and continuous intravenous blinatumomab 28 μg over 24 h for 28 days each cycle, followed by ponatinib monotherapy.
Number of subjects: 90
Study 36402148 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO support for refractory COVID-19
Number of subjects: 1215
Study 36402362 — intervention group
Group type: EXPERIMENTAL
Intervention: Barometric pressure intervention, specific details not provided.
Number of subjects: 0
Study 36402362 — intervention group
Group type: COMPARATOR
Intervention: Control group, specific details not provided.
Number of subjects: 0
Study 36402456 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved bone marrow from deceased organ donors (VB-derived HPCs)
Number of subjects: 250
Study 36402456 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow aspirated from living donors (iliac crest)
Number of subjects: 250
Study 36402744 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel radiation therapy schedule (3.96 Gy × 7 followed by 1.0 Gy × 9)
Number of subjects: 14
Study 36402744 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel radiation therapy schedule
Number of subjects: 14
Study 36402752 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1-targeting chimeric switch receptor (PD-L1.BB CSR) modified CAR-T cells
Number of subjects: 0
Study 36402752 — intervention group
Group type: COMPARATOR
Intervention: Conventional 2nd-generation CAR-T cells
Number of subjects: 0
Study 36402958 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical staff measuring VA function (Assessor 1)
Number of subjects: 612
Study 36402958 — intervention group
Group type: COMPARATOR
Intervention: Reference standard (Assessor 2)
Number of subjects: 612
Study 36402958 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility questionnaires and semi-structured interviews
Number of subjects: 612
Study 36402970 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular decompression (MVD)
Number of subjects: 115
Study 36403022 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-CF bronchiectasis patients (BE group)
Number of subjects: 61
Study 36403022 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (HC group)
Number of subjects: 61
Study 36403075 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm reduction (HR) organization services
Number of subjects: 20
Study 36403075 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination
Number of subjects: 20
Study 36403075 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health and financial wellbeing
Number of subjects: 20
Study 36403075 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug quality
Number of subjects: 20
Study 36403075 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in healthcare providers
Number of subjects: 20
Study 36403579 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.8 mg/kg) plus nivolumab (3 mg/kg) intravenously starting 30-60 days after autologous HSCT for up to 8 cycles.
Number of subjects: 59
Study 36403579 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin plus nivolumab
Number of subjects: 59
Study 36403700 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C
Number of subjects: 0
Study 36403700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36403862 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenopausal risk-reducing salpingo-oophorectomy
Number of subjects: 368
Study 36403862 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal risk-reducing salpingo-oophorectomy
Number of subjects: 368
Study 36403926 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of hyperreflective foci (HRF)
Number of subjects: 158
Study 36403926 — intervention group
Group type: COMPARATOR
Intervention: Subretinal drusenoid deposits (SDD) only
Number of subjects: 158